Real‐World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database
Neuropsychopharmacology Reports · 2026-06 · 46 (2)
DOI: 10.1002/npr2.70133 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 03.06.2026. Verfasst von Masaki Kato und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan. Hauptthemen laut MEDLINE: Antidepressive Agents, Major Depressive Disorder, Practice Patterns, Physicians', Vortioxetine. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Ltd.
Abstract (Originalsprache)
Aim
Vortioxetine has been approved for the treatment of patients with major depressive disorder (MDD) in Japan since 2019; however, limited data are available on its use in clinical practice. This study aimed to identify real‐world prescribing patterns for first‐line antidepressant treatment of patients with MDD in Japan, and to understand how patient characteristics influence treatment selection and continuation.
Methods
This retrospective cohort study utilized data from the JMDC claims database. Patients with MDD (aged ≥ 18 years) were included if they were newly prescribed antidepressants between November 1, 2019 and May 31, 2024. The primary outcome was the distribution of antidepressants prescribed as first‐line treatment. Secondary outcomes included evaluating treatment patterns and characteristics among patients receiving a single antidepressant as first‐line therapy.
Results
The analysis population included 263 773 patients, of whom 97.4% had single‐drug prescriptions (vortioxetine [10.2%], selective serotonin reuptake inhibitors [48.3%], serotonin–norepinephrine reuptake inhibitors [15.2%], noradrenergic and specific serotonergic antidepressants [9.8%], and other antidepressants [13.9%]), and 2.6% had multiple‐drug prescriptions. Patients were less likely to be prescribed vortioxetine if they were female (odds ratio: 0.802; 95% confidence interval: 0.781–0.824) or older than 60 years (0.544; 0.498–0.594), whereas patients with somnolence (2.248; 1.152–4.385), adjustment disorders (1.488; 1.433–1.544), and nausea and vomiting (1.253; 1.194–1.315) were more likely to be prescribed vortioxetine. In the first 3 months after initiating vortioxetine treatment, 41.3% of patients continued treatment, 44.7% discontinued, and 14.0% changed treatment. Treatment change was more common in women (1.129; 1.046–1.218), and in patients with physical symptoms, whereas mental health‐related comorbidities were associated with treatment persistence.
Conclusion
These findings suggest that vortioxetine is more commonly prescribed to working‐age men in Japan, and that patient characteristics and tolerability considerations contribute to prescribing and continuation patterns in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan.
- Japan Medical Office, Takeda Pharmaceutical Co., Ltd, Tokyo, Japan.
ORCID-Profile: Masaki Kato, Tatsuya Hoshino, Yayoi Kawata, Fumie Tokuda, Shinji Fujimoto
Förderung
- Takeda Pharmaceutical Company Ltd
Zitieren
APA
Kato, M., Hoshino, T., Kawata, Y., Tokuda, F., & Fujimoto, S. (2026). Real‐World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database. Neuropsychopharmacology Reports, 46(2). https://doi.org/10.1002/npr2.70133
Vancouver
Kato M, Hoshino T, Kawata Y, Tokuda F, Fujimoto S. Real‐World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database. Neuropsychopharmacology Reports. 2026;46(2). doi:10.1002/npr2.70133
BibTeX
@article{Kato2026,
author = {Kato, Masaki and Hoshino, Tatsuya and Kawata, Yayoi and Tokuda, Fumie and Fujimoto, Shinji},
title = {Real‐World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database},
journal = {Neuropsychopharmacology Reports},
year = {2026},
volume = {46},
number = {2},
doi = {10.1002/npr2.70133}
}
EUVIMED